Cell-Reactive Compstatin Analogs for Sustained Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing approaches to inhibiting complement activation are inadequate for various therapeutic purposes, particularly in conditions like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), ischemia/reperfusion injury, transplant rejection, and chronic respiratory disorders, due to the lack of effective and targeted complement inhibitors.
Innovation Solution
Development of cell-reactive, long-acting, and targeted compstatin analogs that can be administered to protect cells from complement-mediated damage and treat complement-mediated disorders by inhibiting complement activation, including compositions and methods for making and using these analogs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional complement inhibitors are used, then complement activation is inhibited to some extent, but the therapeutic effect is inadequate for treating serious diseases like PNH, aHUS, and transplant rejection
Solution Approach 1:
The patent modifies the compstatin peptide structure by changing amino acid parameters (substituting residues at specific positions) to create analogs with enhanced complement inhibitory activity. These parameter changes in the peptide sequence result in improved therapeutic effectiveness across multiple complement-mediated disorders while maintaining specificity for the C3 convertase enzyme.
Solution Approach 2:
The invention creates composite peptide structures by combining compstatin with various moieties including cell-reactive groups, PEG chains, and targeting moieties. These composite structures provide both complement inhibition and additional functions such as cell attachment, prolonged circulation, and targeted delivery to specific tissues affected by complement-mediated pathology.
2Duration of action of moving object
If short-acting compstatin analogs are used, then complement activation is inhibited temporarily, but the duration of protection is insufficient for clinical therapy
Solution Approach 1:
The patent achieves continuous complement inhibition by conjugating compstatin analogs to cell-reactive moieties that enable the peptide to remain associated with cell surfaces. This continuous attachment ensures sustained therapeutic protection against complement-mediated damage without requiring repeated dosing, as the analogs persist on target cells throughout the disease process.
Solution Approach 2:
The invention uses cell-reactive moieties as intermediaries to bridge the compstatin analog and target cells. These moieties facilitate prolonged residence time of the analog on cell surfaces by mediating attachment to cellular components, thereby extending the duration of complement inhibition beyond the natural half-life of the free peptide.
3Reliability
If non-targeted complement inhibitors are used, then complement activation is inhibited systemically, but off-target effects and lack of specificity reduce therapeutic index
Solution Approach 1:
The patent imparts local quality to the compstatin analog by equipping it with a targeting moiety that directs the peptide to specific tissues or cell types affected by complement-mediated pathology. This localization ensures that complement inhibition occurs primarily at the site of disease pathology rather than systemically, improving therapeutic index while reducing off-target effects.
Solution Approach 2:
The targeting moiety serves as an intermediary that guides the compstatin analog to specific target cells or tissues through selective binding to ligands or receptors expressed on or near affected cells. This intermediary function enables selective delivery of the complement-inhibiting activity to sites where it is most needed, enhancing specificity without requiring complex external delivery systems.
Data Source
AI summary
In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. in some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ, In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.